RN

RN-1747 is a selective transient receptor potential cation channel subfamily V member 4 agonist (EC50: hTRPV4 of 0.77 μM, mTRPV4 of 4.0 μM, and rTRPV4 of 4.1 μM) and also acts as an antagonist for TRPM8 (IC50: 4 μM).

RN-18 is an inhibitor of HIV-1 viral infectivity factor (IC50: 6 μM in nonpermissive H9 cells).

RN486 is an effective and specific BTK inhibitor (IC50: 4 nM).

RN-1 dihydrochloride is an effective and selective irreversible inhibitor of lysine-specific demethylase 1 (LSD1, IC50 = 70 nM).

RN941 is a highly potent Bruton's tyrosine kinase (BTK) inhibitor.

RN9893 is a selective and potent TRPV4 receptor antagonist with IC50 values of 320, 420 and 660 nM for TRPV4 receptors in mouse, human and rat, respectively.

RN983 is a potent and selective BTK inhibitor.

RN-9893 is an antagonist of transient receptor potential vanilloid 4 (TRPV4; IC50s = 0.42 and 0.66 μM, respectively, for the human and rat receptors).1 It is selective for TRPV4 over TRPV1, TRPV3, and TRPM8 (IC50s = 10, >30, and 30 μM, respectively). RN-9893 reduces rat TRPV4 activity induced by 4α-phorbol 12,13-didecanoate or hypotonicity (IC50s = 0.57 and 2.1 μM, respectively, in cell free assays). |1. Wei, Z.L., Nguyen, M.T., O'Mahony, D.J., et al. Identification of orally-bioavailable antagonists of the TRPV4 ion-channel. Bioorg. Med. Chem. Lett. 25(18), 4011-4015 (2015).

RN-1734 is selective TRPV4 channel antagonist(IC50 of 2.3 μM,5.9 μM,3.2 μM for hTRPV4, mTRPV4 and rTRPV4,respectively)

(E)-KPT330 is a CRM1-selective inhibitor of nuclear export. It inhibits protein trafficking from the nucleus and induces cell cycle arrest and apoptosis in mesothelioma cells.

Bococizumab(PF-04950615) is a humanized mAb against PCSK9 and an inhibitor of the synthesis of PCSK9 in the liver that reduces the amount of low-density lipoprotein cholesterol (LDL-C) in the blood.Bococizumab is used to treat hypercholesterolemia.

Retro-2 cycl is a dihydroquinazolinone (DHQZ) retrograde trafficking inhibitor. Retro-2 cycl (RN 1-001) inhibits JCPyV and HPV16 pseudovirus(IC50s of 54 μM and 160 μM, respectively),with antiviral agent.

Kebuzone is a non-steroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and platelet inhibitory activities.

Fremanezumab (TEV-48125) is a humanised monoclonal antibody targeting CGRP, capable of neutralising human (IC50=7.94 nM), mouse (IC50=19.6 nM) and rat CGRP, and is indicated for the prevention of migraine. Fremanezumab inhibits CGRP's vasodilatory effects in the basilar artery constriction segment and suppresses activation of A-δ and high-threshold (HT) neurons in the meningeal nociceptive system triggered by cortical spreading depression (CSD) in rats. In vitro, Fremanezumab counteracts CGRP's immunosuppressive effects on microglia and lymphocytes.

Ponezumab (PF-04360365) is a humanized monoclonal antibody targeting the C-terminus of beta-amyloid 40 (Abeta40). By binding to Abeta40 in the blood, it establishes a 'peripheral sink' effect, thereby promoting the transfer of amyloid proteins from the central nervous system to the periphery and reducing brain plaque burden. It is primarily used for pharmacological research in Alzheimer's disease and cerebral amyloid angiopathy.

PF-06342674 is a humanized monoclonal antibody targeting the IL-7 receptor-α, with immunoregulatory activity, used in Type 1 diabetes research.

Tanezumab (RN-624) is a humanised monoclonal antibody targeting NGF (nerve growth factor). It inhibits the sensitisation and conduction of peripheral pain fibres by blocking the interaction between NGF and the p75 and TrkA receptors, thereby treating various acute and chronic pain conditions, including osteoarthritis, knee arthritis, and neuropathic pain.

Apalutamide-13C-d3 (RN-509-13C,d3) is a 13C and 2H-labeled version of Apalutamide. Apalutamide is an efficient androgen receptor (AR) antagonist used in the study of prostate diseases.

RN-1665 is a potent and selective TRPV4 receptor antagonist.

RN277 is an inhibitor of LRRK2 type II kinase (LRRK2type II kinase). It serves as a cellular tool targeting the inactive state of LRRK2. In vitro, RN277 inhibits LRRK1 kinase activity and the kinase activity of LRRK2, with an IC50 of 70 nM. Additionally, it reduces Rab8a phosphorylation in a dose-dependent manner. RN277 is useful for Parkinson's disease research.

RN341 is a LRRK2-specific type II kinase inhibitor (IC50 of 296 nM). It prevents the phosphorylation of LRRK2 by stabilizing an open conformation, thereby avoiding S935 dephosphorylation. Additionally, RN341 rescues LRRK2-mediated kinesin motility blockage by preventing microtubule binding. This compound effectively inhibits both wild-type and G2019S LRRK2 at the cellular level, offering a novel avenue for Parkinson's disease research.

Corn oil is a kind of vegetable oil extracted from corn germ. Corn oil is mainly used as a carrier and solvent in scientific research.

Tabernanthalog (TBG) is a 5-HT2A agonist. In rodents,Tabernanthalog has been found to promote structural neuroplasticity, reduce alcohol-seeking and heroin-seeking behavior, and produce antidepressant effects.

Aminoacyl tRNA synthetase-IN-1 is an inhibitor of bacterial aminoacyl tRNA synthetase (aaRS).